Cyclerion Therapeutics, Inc.
Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)

Abstract:

The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of Nonalcoholic Steatohepatitis (NASH).